[{"Assets_0_Q2_USD":1578300000.0,"EarningsPerShareDiluted_2_Q2_USD":-0.39,"EarningsPerShareDiluted_1_Q2_USD":-0.11,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":74100000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":74400000.0,"EarningsPerShareBasic_2_Q2_USD":-0.39,"EarningsPerShareBasic_1_Q2_USD":-0.11,"StockholdersEquityConverted_0_Q2_USD":1077300000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":74100000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":74400000.0,"StockholdersEquity_0_Q2_USD":1077200000.0,"NetIncomeLossConverted_2_Q2_USD":-28900000.0,"NetIncomeLossConverted_1_Q2_USD":-8300000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":13900000.0,"CommonStockSharesOutstanding_0_Q2_shares":74500000.0,"CommonStockSharesConverted_0_Q2_shares":74500000.0,"RevenuesConverted_1_Q2_USD":195100000.0,"RevenuesConverted_2_Q2_USD":381400000.0,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20191231","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20200207"}]